Alveus Therapeutics

Executive Summary

Alveus Therapeutics is a preclinical-stage biopharmaceutical company based in Boston, developing innovative inhaled therapeutics for serious respiratory diseases such as idiopathic pulmonary fibrosis (IPF) and severe asthma. The company leverages a proprietary drug delivery platform that enables precise, sustained targeting of the deep lung, potentially improving efficacy and safety over traditional systemic or inhaled treatments. Since its founding in 2021, Alveus has raised $160 million in funding, reflecting strong investor confidence in its technology and pipeline. With a focus on high unmet needs in respiratory medicine, Alveus is positioned to address key limitations of current therapies, including off-target effects and inadequate drug retention in the lungs. As the company progresses toward clinical development, its platform approach offers scalability across multiple indications, making it a compelling player in the respiratory therapeutics space.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program in IPF70% success
• Q2 2026Series B or C Financing Round80% success
• Q4 2026Partnership or Licensing Deal for Severe Asthma Program60% success